BRAF and melanoma: WM3918, the wild-type melanoma cell line, and WM983BR, the BRAF inhibitor-resistant mutant line, showed no significant shifts in OCR/ECAR ratio with trametinib treatment, indicating that the effect of trametinib was minimal.